A novel tool for the assessment of pulmonary disposition of dry powder aerosols; the isolated and perfused rat lung exposed to budesonide, formoterol and terbutaline

P. Ewing, S. Eirefelt, P. Andersson, A. Blomgren, A. Ryrfeldt, P. Gerde (Stockholm, Lund, Sweden)

Source: Annual Congress 2007 - New treatments for asthma
Session: New treatments for asthma
Session type: Thematic Poster Session
Number: 2127
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Ewing, S. Eirefelt, P. Andersson, A. Blomgren, A. Ryrfeldt, P. Gerde (Stockholm, Lund, Sweden). A novel tool for the assessment of pulmonary disposition of dry powder aerosols; the isolated and perfused rat lung exposed to budesonide, formoterol and terbutaline. Eur Respir J 2007; 30: Suppl. 51, 2127

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Inhaled budesonide causes rapid vasoconstriction in the isolated and perfused rat lung
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008

Inhalation of dry powder INS1009 (DP-INS1009) does not activate the cough reflex in guinea pigs: a comparison with nebulized treprostinil.
Source: International Congress 2017 – Experimental PH
Year: 2017


The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

In vivo pulmonary deposition of aclidinium bromide from a multidose dry powder inhaler
Source: Annual Congress 2008 - Novel treatments for respiratory disease
Year: 2008



Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

Young children with asthma treated with budesonide inhalation suspension can successfully be transitioned to once-daily budesonide dry powder inhaler
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007


Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler
Source: Eur Respir J 2007; 30: Suppl. 51, 100s
Year: 2007

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi
Source: Eur Respir J 2007; 29: 575-581
Year: 2007



Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser
Source: Eur Respir J 2007; 30: Suppl. 51, 29s
Year: 2007

Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004

Efficacy of formoterol 12μg dry powder capsules in 6,155 asthmatic patients poorly controlled with salmeterol or on-demand salbutamol (EFORA study)
Source: Eur Respir J 2002; 20: Suppl. 38, 107s
Year: 2002

In vitro delivery of formoterol via a novel multi-dose dry powder inhaler, at clinically relevant inspiratory flow rates
Source: Eur Respir J 2003; 22: Suppl. 45, 472s
Year: 2003

Gamma-scintigraphic evaluation of the delivered dose, lung deposition rate and distribution pattern of 99mTc-labelled tiotropium via dry powder inhaler
Source: Eur Respir J 2003; 22: Suppl. 45, 475s
Year: 2003

Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler
Source: Eur Respir J 2007; 30: Suppl. 51, 350s
Year: 2007

Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

In-use in vitro performance of formoterol fumarate dihydrate powder for inhalation (6 and 12 µg/dose) delivered from a novel multidose dry powder inhaler
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI)
Source: Eur Respir J 2005; 26: Suppl. 49, 126s
Year: 2005